CYTOMX THERAPEUTICS INC (CTMX) Stock Price, Forecast & Analysis
USA - NASDAQ:CTMX - US23284F1057 - Common Stock
CTMX Key Statistics, Chart & Performance
The current stock price of CTMX is 3.57 USD. In the past month the price increased by 8.18%. In the past year, price increased by 240%.
CTMX Latest News, Press Relases and Analysis
CTMX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 20.59 | 385.18B | ||
| AMGN | AMGEN INC | 13.68 | 160.66B | ||
| GILD | GILEAD SCIENCES INC | 14.63 | 148.64B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 25.12 | 109.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 14.48 | 69.08B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 350.8 | 59.78B | ||
| ARGX | ARGENX SE - ADR | 61.77 | 50.39B | ||
| INSM | INSMED INC | N/A | 40.08B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5.01 | 34.10B | ||
| NTRA | NATERA INC | N/A | 27.30B | ||
| BNTX | BIONTECH SE-ADR | N/A | 24.98B | ||
| BIIB | BIOGEN INC | 9.22 | 22.62B |
Related stock screener links
About CTMX
Company Profile
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 119 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
Company Info
CYTOMX THERAPEUTICS INC
151 Oyster Point Blvd., Suite 400
South San Francisco CALIFORNIA 94080 US
CEO: Sean A. McCarthy
Employees: 120
Phone: 16505153185
CYTOMX THERAPEUTICS INC / CTMX FAQ
What does CTMX do?
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company is headquartered in South San Francisco, California and currently employs 119 full-time employees. The company went IPO on 2015-10-08. The firm is focused on developing conditionally activated, masked biologics designed to be localized to the tumor microenvironment. The firm is developing a pipeline of localized biologics, through its PROBODY therapeutic platform. Its pipeline comprises therapeutic candidates across multiple treatment modalities, including ADCs, T-cell engagers, and immune modulators such as cytokines. Its clinical-stage pipeline includes CX-2051, CX-904 and CX-801. CX-2051 is a masked, conditionally activated ADC directed toward EpCAM, armed with a topoisomerase-1 inhibitor payload. CX-904 is a masked, conditionally activated T-cell-engaging bispecific antibody targeting the EGFR on tumor cells and the CD3 receptor on T cells. CX-801 is a masked interferon alpha-2b PROBODY cytokine with broad potential applicability in traditionally immuno-oncology-sensitive as well as insensitive (cold) tumors.
What is the stock price of CYTOMX THERAPEUTICS INC today?
The current stock price of CTMX is 3.57 USD. The price increased by 7.21% in the last trading session.
Does CYTOMX THERAPEUTICS INC pay dividends?
CTMX does not pay a dividend.
How is the ChartMill rating for CYTOMX THERAPEUTICS INC?
CTMX has a ChartMill Technical rating of 10 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the employee count for CTMX stock?
CYTOMX THERAPEUTICS INC (CTMX) currently has 120 employees.
Can you provide the upcoming earnings date for CYTOMX THERAPEUTICS INC?
CYTOMX THERAPEUTICS INC (CTMX) will report earnings on 2025-11-06, after the market close.
Can you provide the short interest for CTMX stock?
The outstanding short interest for CYTOMX THERAPEUTICS INC (CTMX) is 19.54% of its float.
CTMX Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to CTMX. When comparing the yearly performance of all stocks, CTMX is one of the better performing stocks in the market, outperforming 97.55% of all stocks.
CTMX Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to CTMX. While CTMX has a great health rating, its profitability is only average at the moment.
CTMX Financial Highlights
Over the last trailing twelve months CTMX reported a non-GAAP Earnings per Share(EPS) of 0.57. The EPS increased by 306.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 34.01% | ||
| ROA | 27.41% | ||
| ROE | 40.02% | ||
| Debt/Equity | 0 |
CTMX Forecast & Estimates
14 analysts have analysed CTMX and the average price target is 5.9 USD. This implies a price increase of 65.31% is expected in the next year compared to the current price of 3.57.
For the next year, analysts expect an EPS growth of -93.05% and a revenue growth -23.36% for CTMX